Skip to main content
Medical information Clinical review pending

Genetic Testing

CALR3 Gene Cardiomyopathy Familial Hypertrophic Type 19 Genetic Test

Genetic test to identify mutations in the CALR3 gene associated with Familial Hypertrophic Cardiomyopathy (HCM). Helps in understanding genetic risk for this heart condition.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (collected in an appropriate tube), Extracted DNA, or One drop of blood on an FTA card.
Results
3 to 4 Weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CALR3 Gene Cardiomyopathy Familial Hypertrophic Type 19 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of Hypertrophic Cardiomyopathy (HCM)
  • ✓Unexplained heart failure
  • ✓Symptoms suggestive of HCM (e.g., shortness of breath, chest pain, palpitations, fainting)
  • ✓Personal history of HCM
  • ✓Risk assessment for family members of HCM patients
  • ✓Genetic counseling for cardiovascular risk
02

In plain language

What this test helps you understand

Identifies mutations in the CALR3 gene associated with Familial Hypertrophic Cardiomyopathy (HCM). Aids in risk assessment for individuals with a family history or symptoms suggestive of HCM.
The CALR3 Gene Cardiomyopathy Familial Hypertrophic Type 19 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to familial hypertrophic cardiomyopathy (HCM). HCM involves the abnormal thickening of the heart muscle, potentially leading to serious cardiovascular issues. Understanding your genetic predisposition is important for early diagnosis and management.

This test specifically looks for mutations in the CALR3 gene. By analyzing your genetic material, the test can provide insights into your likelihood of developing HCM.

Individuals with a family history of HCM, unexplained heart failure, or symptoms like shortness of breath, chest pain during exertion, palpitations, fainting, or dizziness may benefit from this test. A family history of cardiovascular diseases, especially HCM, is a key consideration.

Taking this test can lead to early detection of genetic predispositions to HCM, enabling informed decisions about lifestyle and treatment. It can also help guide family members about their potential risk and improve overall cardiovascular health management.

Results will indicate the presence or absence of mutations in the CALR3 gene. Discussing your results with a healthcare provider or genetic counselor is recommended to understand the implications and develop a personalized management plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing.
SampleBlood sample (collected in an appropriate tube), Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the CALR3 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes the CALR3 gene. HCM can be caused by mutations in other genes. A negative result does not completely rule out HCM. Interpretation of results requires clinical correlation and may benefit from genetic counseling.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

HCM is a condition where the heart muscle becomes abnormally thick, which can affect the heart's ability to pump blood effectively and may lead to serious complications.
Individuals with a family history of HCM, unexplained heart failure, or symptoms like shortness of breath, chest pain, palpitations, or fainting should discuss this test with their doctor.
This test specifically looks for mutations in the CALR3 gene, one of the genes associated with HCM.
Your results will indicate if any mutations in the CALR3 gene were found. Discussing these results with your doctor or a genetic counselor is important to understand their meaning and implications for your health.
While not always mandatory, genetic counseling before and after testing is highly recommended to understand the test, interpret results, and discuss potential implications for you and your family.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp